Navigation Links
Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
Date:8/29/2013

KANSAS CITY, Kan., Aug. 29, 2013 /PRNewswire/ -- Aratana Therapeutics (Nasdaq: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets (pet therapeutics), today announced that it will host a Pet Therapeutics Primer and Product Update Event, to be held September 11, 2013, at the Four Seasons Hotel in Boston. 

The purpose of the event is to comprehensively lay out the pet therapeutics regulatory framework and to provide a detailed program-by-program update on Aratana's current pet therapeutic development programs.Event:Pet Therapeutics Primer & Product UpdateDate: Wednesday, September 11, 2013 Time: 6:00 – 7:30 p.m. (Eastern Time) Location:Parris Room; Four Seasons Hotel BostonThe event will be webcast live beginning with the company presentations at 6:30 p.m. Eastern Time, and will then be made available as an archive on the Aratana Therapeutics website at aratana.investorroom.com.

Program Agenda:
Dr. Steven St. Peter, President and Chief Executive Officer of Aratana Therapeutics, will provide a brief introduction to the Company and its pipeline of pet therapeutic product candidates.  He also will discuss Aratana's licensing and partnership strategy for expanding its development pipeline.

Dr. Linda Rhodes, Aratana's Chief Scientific Officer, will provide an overview of the regulatory framework at the FDA's Center for Veterinary Medicine; specifically, the three concurrent regulatory work-streams: safety, efficacy and manufacturing.  Dr. Rhodes also will discuss the mechanics of filing an administrative New Animal Drug Application (NADA) and the subsequent notification of approval.&
'/>"/>

SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Aratana Therapeutics Reports Second Quarter 2013 Financial Results
2. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Aratana Therapeutics to Present at Two Upcoming Healthcare Conferences
4. Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
5. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
6. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
7. Aratana to Participate in Leerink Swanns November Management Access Days
8. Carolus Therapeutics and The Alpha-1 Project Collaborate to Validate CT-2009 Target as Important in Human Disease
9. Echo Therapeutics Announces Management Changes
10. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
11. aTyr Pharma Expands Executive Leadership Team to Support Development of New Therapeutics Based on Physiocrine Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... , MUMBAI, India, Sept. 30 A 17-year-old ... become the first person in India to be treated using ... Medical Systems (NYSE: VAR ) and BrainLAB. Doctors at ... radiosurgery treatment in a single session that took just a ...
... Mylan Inc. (Nasdaq: MYL ) today announced that ... the U.S. Food and Drug Administration (FDA) for its ... Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg. , Carbidopa ... Myers Squibb,s Parkinson,s treatment Sinemet®, 10mg/100mg, 25mg/100mg and 25mg/250 ...
Cached Medicine Technology:Pioneering Brain Malformation Treatment Performed Using Novalis Tx(TM) Radiosurgery Technology in India 2Pioneering Brain Malformation Treatment Performed Using Novalis Tx(TM) Radiosurgery Technology in India 3Pioneering Brain Malformation Treatment Performed Using Novalis Tx(TM) Radiosurgery Technology in India 4
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... NY, April 17, 2014U.S. military personnel who served ... impact" concussive traumatic brain injury (TBI) were compared ... for other medical reasons. Differences in measures of ... 6-12 months after injury are reported in an ... peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ...
(Date:4/17/2014)... affects about one in five infants in the United ... the first several months after birth. Research into probiotic ... however, the April 1, 2014 issue of the ... a study, "Probiotics and Infant Colic," concluding that the ... infant colic did not reduce crying or fussing ...
(Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
(Date:4/17/2014)... not uncommon these days to find a colored ribbon representing ... breast cancer. But what color ribbon does one think of ... designated color, for many suffering from the disease, black may ... University study consisting of lung cancer patients, primarily smokers between ... more light on the stigma often felt by these patients, ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... , PITTSBURGH , Feb. 5 ... first Visionworks® location in western PA.  Visionworks is a full-service ... designer frames along with contact lenses at value prices. One ... will debut its first local store in the Cranberry Commons ...
... ... special Valentine,s Day giveaway to fans of their Creams N, Lotions Facebook page or followers ... skin soft & naughty” gift basket . , ... Southfield, MI (PRWEB) February 5, 2010 -- Reforma Group is announcing a ...
... YORK , Feb. 5 Nutrition Management Services ... that its Board of Directors unanimously approved the termination of ... Act of 1934, as amended. The Company will file a ... to effect this on or about February 12, 2010 ...
... , , Medtronic Featured as Official Sponsor , ... Association of Heart Failure Nurses (AAHFN) is pleased to promote Heart ... , The purpose of Heart Failure Awareness Week is to increase ...  AAHFN will achieve this goal through the Heart Failure Awareness Week ...
... ... that was first spotted at San Francisco,s famed PIER 39 docks, was successfully rescued, rehabilitated ... Despite rainy skies, a crowd assembled at Rodeo Beach in the Marin Headlands, Sausalito, CA ... , ...
... warning on Tysabri label, but says benefits still outweigh ... the latest blow to the controversial multiple sclerosis drug ... announced that it was slapping a new warning on ... health-care professionals and patients, the FDA warned that the ...
Cached Medicine News:Health News:Visionworks(R) Brings High Quality Eye Care & Eye Wear to Cranberry 2Health News:Visionworks(R) Brings High Quality Eye Care & Eye Wear to Cranberry 3Health News:Romantic Valentine's Day Gift Ideas: Keep Your Skin Soft & Naughty Gift Basket Giveaway 2Health News:Nutrition Management Services Company Announces Decision to Deregister its Class A Common Stock 2Health News:AAHFN Promotes Heart Failure Awareness Week Through Webinar 2Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 2Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 3Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 4Health News:More Doses of MS Drug Raise Risk of Brain Infection 2Health News:More Doses of MS Drug Raise Risk of Brain Infection 3
... Most readers available today operate with ... (which reduces speed) or use an imaging ... (which reduces sensitivity and the individual signals ... includes a miniature lens array containing 96 ...
... The FLx800 is designed to combine ... ease of use. This design incorporates powerful ... traditional fluorescence microplate readers. The FLx800 line ... the specific needs of research and OEM ...
The DELFIA Platewash is a general purpose microtitration plate and strip washer especially standardized for use with DELFIA diagnostic kits....
Easy to use , Allow for a flexible washing , Uniform and efficient , Very robust and reliable , Adjustable to all well shapes , Rack included (not autoclavable) , Autoclavable at 121C , No e...
Medicine Products: